FilingSEC EDGAR8-K
Benitec Biopharma Reports Fiscal 2026 Results and Provides BB-301 Clinical Update
· SEC accepted
StagePhase 1b/2a
Filing content
The company reported a net loss of $45.5 million for fiscal 2026 and announced the completion of follow-up for Cohort 1 and full enrollment for Cohort 2 in the BB-301 Phase 1b/2a trial.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…